Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease

Annals of Neurology

Volumn 72, Issue 5, 2012, Pages 788-798

  Shi, Ju ^a   Wang, Qian ^a   Johansson, Jenny U ^a   Liang, Xibin ^a   Woodling, Nathaniel S ^a   Priyam, Prachi ^a   Loui, Taylor M ^a   Merchant, Milton ^a   Breyer, Richard M ^b   Montine, Thomas J ^c   Andreasson, Katrin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; GLUCOSE TRANSPORTER 1; POSTSYNAPTIC DENSITY PROTEIN 95; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; SYNAPSIN I; SYNAPTOBREVIN 2; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; AIF1 PROTEIN, HUMAN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; DNA BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MAP2 PROTEIN, HUMAN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; PEPTIDE FRAGMENT; PROSTAGLANDIN SYNTHASE; PTGER3 PROTEIN, MOUSE; SECRETASE;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; AGE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; ENCEPHALITIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MILD COGNITIVE IMPAIRMENT; MUTATION; NERVE CELL; NEWBORN; PATHOLOGY; PHYSIOLOGY;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CELLS, CULTURED; DINOPROSTONE; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENCEPHALITIS; FEMALE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MILD COGNITIVE IMPAIRMENT; MUTATION; NEURONS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

MLCS; MLOWN;

EID: 84871955193     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23677     Document Type: Article

References (52)

1. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421. (Pubitemid 30349107)
2. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology 2004; 23: 159-169. (Pubitemid 38980441)
3. Stewart WF, Kawas C, Corrada M, Metter EJ,. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-632. (Pubitemid 27120096)
4. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521. (Pubitemid 33144916)
5. McGeer PL, Schulzer M, McGeer EG,. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-432. (Pubitemid 26324038)
6. Vlad SC, Miller DR, Kowall NW, Felson DT,. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70: 1672-1677. (Pubitemid 351644133)
7. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011; 7: 402-411.
8. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216. (Pubitemid 33051236)
9. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator- activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410.
10. Tegeder I, Pfeilschifter J, Geisslinger G,. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-2072. (Pubitemid 32927924)
11. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003; 289: 2819-2826. (Pubitemid 37430117)
12. Soininen H, West C, Robbins J, Niculescu L,. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23: 8-21. (Pubitemid 46005786)
13. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204-1215. (Pubitemid 40720980)
14. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68: 1800-1808. (Pubitemid 46791392)
15. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008; 65: 896-905. (Pubitemid 352008472)
16. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG,. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry 2012; 27: 364-374.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD,. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690. (Pubitemid 32385902)
18. Montine TJ, Sidell KR, Crews BC, et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 1999; 53: 1495-1498. (Pubitemid 29491943)
19. Combrinck M, Williams J, De Berardinis MA, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77: 85-88. (Pubitemid 43022699)
20. Andreasson K,. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010; 91: 104-112.
21. Montine TJ, Milatovic D, Gupta RC, et al. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 2002; 83: 463-470. (Pubitemid 35191411)
22. Liang X, Wang Q, Hand T, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 2005; 25: 10180-10187. (Pubitemid 41636214)
23. Liang X, Wang Q, Shi J, et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 2008; 64: 304-314.
24. Shie FS, Breyer RM, Montine TJ,. Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol 2005; 166: 1163-1172. (Pubitemid 40524440)
25. Keene CD, Chang RC, Lopez-Yglesias AH, et al. Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol 2010; 177: 346-354.
26. Jin J, Shie FS, Liu J, et al. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation 2007; 4: 2.
27. Jankowsky JL, Slunt HH, Ratovitski T, et al. Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng 2001; 17: 157-165. (Pubitemid 32409891)
28. Jewell ML, Breyer RM, Currie KP,. Regulation of calcium channels and exocytosis in mouse adrenal chromaffin cells by prostaglandin EP3 receptors. Mol Pharmacol 2011; 79: 987-996.
29. Li J, Liang X, Wang Q, Breyer RM, et al. Misoprostol, an anti-ulcer agent and PGE(2) receptor agonist, protects against cerebral ischemia. Neurosci Lett 2008; 438: 210-215.
30. Yang T, Knowles JK, Lu Q, et al. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One 2008; 3: e3604.
31. Piermartiri TC, Figueiredo CP, Rial D, et al. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol 2010; 226: 274-284.
32. Shi J, Johansson J, Woodling NS, et al. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 2010; 184: 7207-7218.
33. Liang X, Lin L, Wang Q, et al. Neuronal and vascular protection by the prostaglandin E2 EP4 receptor in a mouse model of cerebral ischemia. J Clin Invest 2011; 121: 4362-4371.
34. Melnikova T, Savonenko A, Wang Q, et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006; 141: 1149-1162. (Pubitemid 44128685)
35. Passos GF, Figueiredo CP, Prediger RD, et al. Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Brain Behav Immun 2010; 24: 493-501.
36. Kim DH, Jung WY, Park SJ, et al. Anti-amnesic effect of ESP-102 on Abeta(1-42)-induced memory impairment in mice. Pharmacol Biochem Behav 2010; 97: 239-248.
37. Yoshiike Y, Kimura T, Yamashita S, et al. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One 2008; 3: e3029.
38. Savonenko A, Xu GM, Melnikova T, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 2005; 18: 602-617. (Pubitemid 40332718)
39. Minkeviciene R, Ihalainen J, Malm T, et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 2008; 105: 584-594. (Pubitemid 351562711)
40. Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002; 10: 279-288. (Pubitemid 35217581)
41. Apelt J, Bigl M, Wunderlich P, Schliebs R,. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci 2004; 22: 475-484. (Pubitemid 39311436)
42. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC,. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002; 59: 1381-1389. (Pubitemid 35014802)
43. Holsinger RM, McLean CA, Beyreuther K, et al. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 2002; 51: 783-786. (Pubitemid 34568861)
44. Yang LB, Lindholm K, Yan R, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003; 9: 3-4. (Pubitemid 36098241)
45. Borghi R, Patriarca S, Traverso N, et al. The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging 2007; 28: 1009-1014. (Pubitemid 46635907)
46. Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in neurodegenerative diseases: A similar pattern. Neurobiol Aging 2009; 30: 759-768.
47. Walter S, Letiembre M, Liu Y, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem 2007; 20: 947-956. (Pubitemid 350059737)
48. Lazarus M, Yoshida K, Coppari R, et al. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci 2007; 10: 1131-1133. (Pubitemid 47339949)
49. Ushikubi F, Segi E, Sugimoto Y, et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998; 395: 281-284. (Pubitemid 28447553)
50. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306: 1954-1957. (Pubitemid 39627863)
51. Funk CD, FitzGerald GA,. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-479. (Pubitemid 350146448)
52. Montine TJ, Sidell KS, Crews BC, et al. Elevated cerebrospinal fluid prostaglandin E2 levels in patients with probable Alzheimer's disease. Neurology 1998; 53: 1495-1498.